Skip to main content

Trace Element Excess

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Rare Disease Therapeutics
1 program
Chromium Contamination of Parenteral NutritionN/A1 trial
Active Trials
NCT03906890Completed75Est. Sep 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rare Disease TherapeuticsChromium Contamination of Parenteral Nutrition

Clinical Trials (1)

Total enrollment: 75 patients across 1 trials

NCT03906890Rare Disease TherapeuticsChromium Contamination of Parenteral Nutrition

Chromium Contamination of Parenteral Nutrition

Start: Feb 2018Est. completion: Sep 201975 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.